MEPOLIZUMAB

Brand name:

• Nucala®

Pharmaceutical company:

GlaxoSmithKline Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Uncontrolled severe asthma

PBAC Submission type:

Change to existing listing (Category 3)

Comment:

--

Public Summary Document:

Not yet available

Related medicines:

--

Submission received for:

March 2024 PBAC meeting

Opportunity for consumer comment:

Open 22/11/2023 and close 31/01/2024 (see PBS Website)

PBAC meeting:

Held on 13/03/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

13/05/2024

Lodgement of required documentation:

17/05/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 06/06/2024

Status:

Finalised

Government processes:

Commenced on 06/06/2024

Medicine listed on the PBS:

01/10/2024 (see PBS schedule)

---